Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Baxter
Medtronic
Johnson and Johnson
Dow
Harvard Business School

Last Updated: December 7, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Famitinib

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Famitinib?

Famitinib is an investigational drug.

There have been 15 clinical trials for Famitinib. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2015.

The most common disease conditions in clinical trials are Carcinoma, Lung Neoplasms, and Carcinoma, Non-Small-Cell Lung. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Sun Yat-sen University, and Fudan University.

There are eight US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Famitinib
TitleSponsorPhase
A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS)Fudan UniversityPhase 2
Famitinib Plus Camrelizumab Versus Famitinib Alone in Advanced OsteosarcomaJiangsu HengRui Medicine Co., Ltd.Phase 1/Phase 2
Famitinib Plus Camrelizumab Versus Famitinib Alone in Advanced OsteosarcomaPeking University Shougang HospitalPhase 1/Phase 2

See all Famitinib clinical trials

Clinical Trial Summary for Famitinib

Top disease conditions for Famitinib
Top clinical trial sponsors for Famitinib

See all Famitinib clinical trials

US Patents for Famitinib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
Famitinib   Start Trial Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Famitinib

Drugname Country Document Number Estimated Expiration Related US Patent
Famitinib Argentina 109919 2036-10-10   Start Trial
Famitinib Australia 2017342022 2036-10-10   Start Trial
Famitinib Brazil 112019007144 2036-10-10   Start Trial
Famitinib Canada 3039760 2036-10-10   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
Baxter
Johnson and Johnson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.